Keith T. Flaherty is Director at Loxo Oncology, Inc. (LOXO). They have made 9 open-market trades across 1 company since 2016, most recently 2024-04-03.
CIK 0001581720
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| LOXO | 35,934 | $8.4M |
Shares reported on the most recent Form 4, priced at the 2018-06-11 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LOXO | SELL | 2018-06-07 | 2018-06-11 | $173.61 | $17.0M | +1.7% | +0.3% | -8.5% |
| LOXO | SELL | 2017-11-20 | 2017-11-22 | $75.99 | $1.1M | +3.1% | +15.4% | +38.4% |
| LOXO | SELL | 2017-08-21 | 2017-08-23 | $72.39 | $775K | +3.2% | +13.4% | -1.6% |
| LOXO | SELL | 2017-05-22 | 2017-05-24 | $45.08 | $649K | +40.0% | +60.4% | +52.4% |
| LOXO | SELL | 2017-02-21 | 2017-02-23 | $41.45 | $601K | -3.4% | +10.7% | +18.9% |
| LOXO | SELL | 2016-12-19 | 2016-12-21 | $30.23 | $438K | -2.9% | +17.0% | +28.9% |
| LOXO | SELL | 2016-09-07 | 2016-09-09 | $30.00 | $435K | -1.3% | -15.9% | -2.6% |
| LOXO | SELL | 2016-08-11 | 2016-08-12 | $26.00 | $390K | +1.6% | +2.9% | -7.5% |
| LOXO | SELL | 2016-08-11 | 2016-08-12 | $26.00 | $390K | +1.6% | +2.9% | -7.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.